IXICO Plc engages in the provision of technology-enabled specialty services to the global biopharmaceutical industry. The firm is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. The company advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.
Osiris One Metals Ltd. 주요 수익원은 Medication Delivery Solutions이며, 최신 수익 발표에서 수익은 4,575,000,000입니다. 지역별로는 United States이 Osiris One Metals Ltd.의 주요 시장이며, 수익은 12,790,000,000입니다.
IXICO plc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Osiris One Metals Ltd.의 순손실은 $0입니다.